2. Academic Validation
  3. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice

Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice

  • Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514. doi: 10.1016/j.bbrc.2018.01.098.
Yujung Jung 1,  Jin-Chul Kim 1,  No-June Park 1,  Sim-Kyu Bong 1,  Sullim Lee 1,  Hyun Jegal 1,  Li Tai Jin 2,  Sang Moo Kim 3,  Yong Kee Kim 4,  Su-Nam Kim 5
Affiliations

Affiliations

  • 1 Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Gangwon-do 25451, Republic of Korea.
  • 2 School of Pharmaceutical Sciences, Key Laboratory of Biotechnology Pharmaceutical Engineering, Wenzhou Medical University, Wenzhou 325000, China.
  • 3 Department of Marine Food Science and Technology, Gangneung-Wonju National University, Gangneung, Gangwon-do 25457, Republic of Korea.
  • 4 College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea.
  • 5 Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Gangwon-do 25451, Republic of Korea. Electronic address: [email protected].
PMID: 29353040 DOI: 10.1016/j.bbrc.2018.01.098
Abstract

Eupatilin (5,7-dihydroxy-3',4',6-trimethoxyflavone) is the main lipophilic flavonoid obtained from the Artemisia species. Eupatilin has been reported to have anti-apoptotic, anti-oxidative and anti-inflammatory activities. Previously, we found that eupatilin increases transcriptional activity and expression of Peroxisome Proliferator-activated Receptor α (PPARα) in a keratinocyte cell line and acts as an agonist of PPARα. PPARα agonists ameliorate atopic dermatitis (AD) and restore the skin barrier function. In this study, we confirmed that the effects of eupatilin improved AD-like symptoms in an oxazolone-induced AD-like mouse model. Furthermore, we found that eupatilin suppressed the levels of serum immunoglobulin E (IgE), interleukin-4 (IL-4), and AD involved cytokines, such as tumor necrosis factor α (TNFα), interferon-γ (IFN-γ), IL-1β, and thymic stromal lymphopoietin (TSLP), IL-33, IL-25 and increased the levels of filaggrin and loricrin in the oxazolone-induced AD-like mouse model. Taken together, our data suggest that eupatilin is a potential candidate for the treatment of AD.

Keywords

Atopic dermatitis; Eupatilin; IL-4; PPARα.

Figures
Products